ArticleJournal of community health2026
COVID-19 Vaccine Coverage and Adverse Event Among Cancer Patients During the 2021-2022 SARS-CoV-2 Outbreaks in Thailand: A Retrospective Cohort Study.
Article in Journal of community health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunocompromised individuals, particularly cancer patients, face elevated risks from COVID-19 and have been prioritized for vaccination in Thailand. However, evidence regarding vaccine coverage and safety in this population remains limited. This study aimed to evaluate COVID-19 vaccination coverage and safety among cancer patients by analyzing the frequency, severity, and risk factors of adverse events following immunization (AEFI). A retrospective cohort of 14,430 patients receiving care at Lopburi Cancer Hospital between January 2021 and December 2022 was analyzed. Demographic and clinical data, vaccination status, and AEFI were obtained from hospital electronic medical records and the national “Mor Prom” digital health platform. Multivariable logistic regression identified factors associated with AEFI. Of the 14,430 patients, 78% received at least one-vaccine dose, and 42% received a booster (> standard two doses). Vaccine sequences varied by following as inactivated vaccines predominated for the first dose (49%), viral vectors for the second (49%), and mRNA for the third (33%). AEFI reports were mostly mild, including fever, injection site reactions, headache, and myalgia. Multivariable analysis identified younger age, female sex, and viral vector vaccines as significant predictors for AEFI. Conversely, metastatic or locally advanced cancer stages were associated with lower odds of adverse events. No severe adverse events exceeded 5% in any group. Considering AEFI, this study suggested that the COVID-19 vaccination demonstrated a favorable safety profile among Thai cancer patients, with manageable adverse events. The findings supported the continued prioritization of vaccination in vulnerable population and provided evidence to alleviate patient concerns regarding vaccine safety.
Indexed as
Identifiers
41866648What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.